The latest price target for Harvard Bioscience (NASDAQ:HBIO) was reported by Benchmark on March 16, 2026. The analyst firm set a price target for $6.00 expecting HBIO to rise to within 12 months (a possible 15.61% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Harvard Bioscience (NASDAQ:HBIO) was provided by Benchmark, and Harvard Bioscience maintained their speculative buy rating.

There is no last upgrade for Harvard Bioscience

The last downgrade for Harvard Bioscience Inc happened on April 9, 2025 when Keybanc changed their price target from N/A to N/A for Harvard Bioscience Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on March 16, 2026 so you should expect the next rating to be made available sometime around March 16, 2027.

While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a maintained with a price target of $0.60 to $6.00. The current price Harvard Bioscience (HBIO) is trading at is $5.19, which is within the analyst’s predicted range.